Kurz gefasst
Übersichtsarbeit in der Zeitschrift PET Clinics, 2023. Verfasst von Anna Sviridenko und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: anna.sviridenko@tirol-kliniken.at. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
Tissue injury in nonmalignant human disease can develop from either disproportionate inflammation or exaggerated fibrotic responses. The molecular and cellular fundamental of these 2 processes, their impact on disease prognosis and the treatment concept deviates fundamentally. Consequently, the synchronous assessment and quantification of these 2 processes in vivo is extremely desirable. Although noninvasive molecular techniques such as 18F-fluorodeoxyglucose PET offer insights into the degree of inflammatory activity, the assessment of the molecular dynamics of fibrosis remains challenging. The 68Ga-fibroblast activation protein inhibitor-46 may improve noninvasive clinical diagnostic performance in patients with both fibroinflammatory pathology and long-term CT-abnormalities after severe COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: anna.sviridenko@tirol-kliniken.at.
- Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Zitieren
APA
Sviridenko, A., di Santo, G., & Virgolini, I. (2023). Imaging Fibrosis. PET Clinics. https://doi.org/10.1016/j.cpet.2023.02.004
Vancouver
Sviridenko A, di Santo G, Virgolini I. Imaging Fibrosis. PET Clinics. 2023. doi:10.1016/j.cpet.2023.02.004
BibTeX
@article{Sviridenko2023,
author = {Sviridenko, Anna and di Santo, Gianpaolo and Virgolini, Irene},
title = {Imaging Fibrosis},
journal = {PET Clinics},
year = {2023},
doi = {10.1016/j.cpet.2023.02.004}
}
EUVIMED